Immune-related Adverse Event Clinical Trial
Official title:
Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype
This study is an open, monocentric study. It includes patients with irAE refractory to standard therapy or patients where corticosteroids cannot be tapered. Patients will either be treated with ECP or second line immunosuppressive therapy according to investigator's choice. Patients will be followed for 24 weeks after first treatment.
At inclusion patient history including type of tumor and immunotherapy will be obtained. At all visits symptoms, changes in concomitant medication, a medical assessment and laboratory investigations will be performed. Blood sampling for safety analysis and for investigating the immunophenotype will be performed at baseline, week 1, 4, 8 and 12. Laboratory values assessed include: - Complete blood count - Chemistry including liver enzymes (AST, ALT) and total bilirubin in the case of immune-related hepatitis, CK in case of myositis, creatinine in case of nephritis - Inflammatory markers: CRP, IL-6, Procalcitonin Peripheral blood mononuclear cells (PBMC) will be used to determine immunophenotype, including the amount of NK-cells, regulatory T- cells and myeloid-derived suppressor cells (MDSC) as well as the expression of inflammatory markers. Biological samples will be frozen for later analysis. Additionally, patients will assess their symptoms and their quality of life by a self-administered questionnaire at baseline and week 4, 8 and 12. Quality of life will be assessed by EORTC QLQ-C30. All irAE will be graded according to CTCAE. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06089967 -
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
|
||
| Recruiting |
NCT05544292 -
Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors
|
||
| Recruiting |
NCT05799898 -
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
|
||
| Not yet recruiting |
NCT06278857 -
SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)
|
Phase 2 | |
| Recruiting |
NCT05813418 -
Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment
|
N/A | |
| Recruiting |
NCT05699915 -
Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors
|
N/A | |
| Recruiting |
NCT05832606 -
Food Intervention to Reduce Immunotherapy toXicity
|
N/A | |
| Recruiting |
NCT06440811 -
Preoperative Adjuvant SOX Plus PL-1 Antibody and FLOT Plus PD-1 Antibody for Locally Advanced dMMR Gastric Cancer
|
Phase 1 | |
| Completed |
NCT05934214 -
EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
|
||
| Recruiting |
NCT06243250 -
Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events
|
||
| Not yet recruiting |
NCT05663775 -
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
|
Phase 2 | |
| Active, not recruiting |
NCT03948724 -
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
|
N/A | |
| Recruiting |
NCT04305145 -
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
|
Phase 2 | |
| Not yet recruiting |
NCT06037811 -
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
|
Phase 2 |